Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

We are shaping the next frontier of medicine with data-powered insights from the Regeneron ... while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed ...

In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in ... our unique ability to repeatedly and consistently translate science into medicine has led to ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

Sanofi licensed the antibody from Alopexx Pharmaceuticals, a precursor to the current biotech of the same name, in 2009 but faced challenges such as the slow enrollment (PDF) of a phase 2a trial.

Distrust over the track record of domestically produced medicine runs deep in China. Such concerns spiraled into public uproar last month over the alleged questionable quality of Chinese generic ...

Sanofi’s Sarclisa has received approval in more than 50 nations and regions. Credit: LCV/Shutterstock. Sanofi’s Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that provide a clearer look at how the Teva-partnered prospect compares to Merck ...

FDA’s Priority Tag to SNY’s Dupixent sBLA for Bullous Pemphigoid Sanofi and Regeneron announced that the FDA has accepted and granted priority review to an sBLA seeking approval of Dupixent ...

The findings of the Stratified Medicine Paediatrics (SMPaeds1) programme, published in the journal Cancer Discovery, demonstrate that circulating tumour DNA (ctDNA) testing can be used to track how ...